GMP CELL THERAPY CONSUMABLES MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)
GMP Cell Therapy Consumables Market, By Product Type (Cell Culture Media and Supplements, Cell Separation and Purification Consumables, Cryopreservation Consumables, Cell Transduction Consumables, Other Consumables), By Cell Type (Stem Cells, T-Cells, Natural Killer (NK) Cells, Other Cell Types), By Application (Oncology, Regenerative Medicine, Neurology, Cardiovascular, Immunology, Other Applications), By End User (Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Academic and Research Institutions, Hospitals and Clinics, Others), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)
In January 2022, Sony Corporation launched the CGX10 Cell Isolation System, which sorts cells at high speed and purity within a closed, sterile environment. This system is crucial for cell-based immunotherapy, used in cancer and autoimmune disorder treatments, where high-purity, viable cells are needed.
In January 2021, Sartorius entered into a strategic partnership with RoosterBio Inc., a prominent supplier of human mesenchymal stem/stromal cells (hMSC). This partnership focuses on scaling up hMSC manufacturing for regenerative medicine. RoosterBio and Sartorius developed a series of GMP-compatible, customer-focused protocols that combined RoosterBio’s hMSC and media systems with Sartorius’s single-use manufacturing technologies, process control software, and cell analysis tools for final hMSC product manufacturing.
In September 2020, Bio-Techne Corporation inaugurated a state-of-the-art, approximately 61,000-square-foot Good Manufacturing Practices (GMP) facility in St. Paul, U.S. The facility is dedicated to large-scale production of GMP-grade materials, crucial for many immuno-oncology and regenerative medicine cell and gene therapy workflows. This facility enables Bio-Techne to meet the growing demand for GMP-grade reagents essential to the expanding cell therapy market.